J&J
released their Q3 results today:
- 2018 Third-Quarter Sales of $20.3 Billion Increased 3.6% versus 2017
- 2018 Third-Quarter EPS was $1.44
- 2018 Adjusted Third-Quarter EPS of $2.05 increased 7.9%*
- Strong Operational Sales and Adjusted EPS Growth*
- Company Increased Sales and EPS Guidance
The Q3 results spawned the following headlines.
-
Reuters: Johnson & Johnson edges past profit estimates, lifts outlook
-
CNBC: Johnson & Johnson beats expectations as cancer drugs, new baby care products help boost sales
-
Bloomberg: J&J's Growing Pharma Unit Helps Company Overcome Currency Woes
-
Bloomberg: J&J Tops 3Q Estimates, Boosts Full-Year Profit Guidance
The growth was largely driven by the pharmaceutical segment and in particular oncology drugs (
Zytiga®,
Imbruvica® and
Darzalex®). Other of the drugs driving the growth are
Tremfya®,
Trinza®,
Simponi®,
Opsumit® and
Uptravi®.
The figures below summarise the Q3 results for each geographic segment, each product segment and for selected pharmaceutical drugs in a historical context.
